A new experimental drug called GanLum, developed by Novartis, shows promise against malaria, particularly against drug-resistant strains. In a trial involving nearly 1,700 participants across 12 African countries, GanLum demonstrated a 99.2% cure rate compared to 96.7% for standard treatments. Experts highlight the urgency of new treatments due to rising drug resistance, especially in Africa, where malaria remains a significant health threat. Teljes cikk (Euronews.com)